

Index

- abortion, spontaneous, *see* spontaneous abortion
 acrosin 361–2, 365
 acrosome reaction 16, 358–9, 361
 actin 76–88
 mRNA synthesis 40, 41
 see also microfilaments
Actinophrys sol 6
 activins 223–4
 adenosine 159, 160–3
 adenylate cyclase 154, 161–2
 adrenergic agonists 267, 270
Aepyornis titan 12, 13
 age
 assisted conception and 407
 chromosomal abnormalities and 101, 316
 IVF success rates and 204, 281, 315, 317–18
 male partner 314
 at menarche 399–400, 401
 oocyte quality and 277–8, 280–2, 313–18
 ageing
 ovarian function and 317–18
 ovulation and 204–5
 physiological oocyte 119, 284–5; chromosomal
 abnormalities and 103–4, 285; morphological
 changes 279
 albumin 13, 14
 alkaline phosphatase staining 120, 121
 alkanols 170
 allopurinol 163
 alpha-1 antitrypsin 283
 alpha 2-macroglobulin 235–6
 alpha fetoprotein 219
 α -amanitin 177, 178
 amenorrhoea
 chemotherapy-induced 318–19
 hypothalamic–pituitary dysfunction 202–4, 298–9
 lactational 400–1
 polycystic ovary disease 299–300
 primary 113
 amino acids 47–8
 amphitoky 4, 11
 ampulla (of oviduct) 254, 255
 oocyte transport 261, 262
 ampullary–isthmic junction (AIJ) 254, 256
 oocyte transport 261, 263
 androgen receptors 211
 androgenesis 4
 androgens
 endometriosis 310
 gonadotrophin therapy and 307
 oocyte quality and 303
 ovarian synthesis 211, 215, 221
 polycystic ovary syndrome 300
 aneuploidy
 factors affecting frequency 100, 101, 104
 human oocytes 95–6, 97, 98
 angiogenic factors 222, 223
 animals
 evolution 1–3
 gametogenesis 8–10
 rights 410
 anisogamy 10, 11
 annulate lamellae 33
 anorexia nervosa 299
 anti-sperm antibodies 296, 312
 anti-zona antibodies 366–9
 antrum, follicular 26–7, 138, 139, 151
 apogamy 10
 apoptosis, *see* programmed cell death
 archigonium 12
 arrhenotoky 4, 11
 ascertainment bias 114
 ascites, ovarian hyperstimulation 345
 assisted conception 331–5, 407–8
 definition 407
 ethical and legal status 352
 historical aspects 331–2
 oocyte recovery techniques 349–51

- assisted conception *continued*
 ovarian stimulation 335–49
 physiological considerations 332
 pregnancy outcome 351–2
 range of techniques 333–5
see also in vitro fertilization
- ATP 48, 161
 meiotic maturation and 174
 oocyte transport and 267
- atresia
 germ cells in fetal ovaries 126–9
 primordial follicles 136–8, 316
- Australopithecus afarensis* 2, 3, 19
- autocrine function 210
- autogamy 4, 6
- autoimmune ovarian failure 319–20
- autonomy, commercial surrogacy and 421–3
- autosomes
 detection of genes 116–17
 ovarian development and 111–12
 premature ovarian failure and 113–14
- B-lymphocytes 229
- B1/B2 repeats 43
- Balbani vitelline body 30
- banking, oocyte 379
- bias, ascertainment 114
- binary fission 4, 5
- bioethics 396–424
- blighted ovum 351
- bovine oocytes
 centrosome inheritance 75
 cytoskeletal organization 67–9, 85–7
 meiotic maturation 156, 158
- BP28 (IGFBP1/PP12) 216–17, 220
- bradykinin 235
- breast cancer 347
- 8-bromo-cAMP (8BrcAMP) 155–6
- bromocriptine 299, 336, 338
 side effects 348–9
- budding 5
- buserelin 288
 IVF-related procedures 341
 polycystic ovary disease 287, 304, 305
- Caenorhabditis elegans* 111
- caffeine 320
- calcium, intracellular 170–3, 197
- calcium ionophores 172
- calphostin C 172
- cancer
 chemotherapy/radiotherapy 318–19
 ovarian stimulation and 347–8
- catecholamines 265
- CD4⁺ T-cells 369
- CD8⁺ T-cells 227–9
- cdc2* gene 179
- cell death
 germ cells 126–9
 programmed, *see* programmed cell death
- CENP-B protein 65
- centrioles 29–30
- centrosomes
 inheritance in mammals 73–6
 mouse fertilization 57, 58, 59, 73–4, 75
 paternal origin 69, 72–3, 89
- cervical mucus 343
- chemotherapy, cancer 318–19
- children
 ovarian development 141–2
 societal attitudes 413, 414–15, 416–17
 spacing 399–401
- cholera toxin 154, 163, 168, 169
- choline 47–8, 166
- chromosomal abnormalities 95–105, 280
 aged oocytes 103–4, 285
 freshly recovered oocytes 95–6
 inseminated-unfertilized oocytes 96–7
 maternal age effects 101, 316
 oocyte maturity and 101
 ovarian stimulation and 99–100, 308
 reproduction and 104–5
 sperm premature chromosome condensation and 102–3
 type of sterility and 98–9
- chromosomes 6
 congression 65, 67, 68
 cryodamage 384
 lampbrush 28–9, 129
 pachytene–diplotene oocytes 28–9, 129, 130, 131
 segregation 65, 67
see also autosomes; X chromosome
- ciliated cells, oviduct epithelium 255, 266–7
- cleavage, first, *see* first cleavage
- cleavage rates 294
 polycystic ovary disease 301
 unexplained infertility 296, 312
- clomiphene (CC) 288, 330, 335–6
 chromosomal abnormalities and 100
 oocyte quality and 308–9
 polycystic ovary disease 287, 304, 305
 side-effects 348
- sperm premature chromosome condensation and 102
 unexplained infertility 338, 339
- coffee 320
- colcemid 81, 84
- concanavalin A 169, 170
- congenital abnormalities 351–2
- contraception 405

- contraceptive vaccines 366–9
 corona–cumulus complexes, oocyte (OCCC) 279, 280
 corpus luteum
 inhibin synthesis 224
 leukocytes 225–6, 227, 229
 prostaglandin actions 234–5
 TNF α actions 232
 cortical granules 31–2
 cryodamage 384–5, 386, 387
 reaction to insemination 293, 359
 cortical region, microfilaments 77–8, 85–7
 cortisol 293–4
 cotinine 322
 cow oocytes, *see* bovine oocytes
 CREST scleroderma 65–7
 Creutzfeldt–Jacob disease 330, 348
 cryobiology 380–82
 cryopreservation
 embryos 376
 oocytes 376–93; action of cryoprotectants 380–81;
 applications 378–9; cellular events 381–2;
 factors influencing success 382–4; history
 377–8; human oocyte study 389–92; possible
 cryodamages 384–5, 386, 387; pregnancy
 outcomes after 392; rabbit oocyte study 387–9;
 survival assessment after 384, 387
 sperm 383
 cryoprotectants 7, 377
 action 380–81
 duration of exposure 383
 culture
 evolution 412–17
 and fertility 401–5
 cumulus cell–enclosed oocytes (CEO) 152, 181
 meiotic arrest 155, 157, 159–60, 161
 meiotic maturation 165, 166, 168–9, 173–6, 177,
 178
 cumulus cell–oocyte complex 47–8, 155, 166, 180–1
 cumulus oophorus 151
 meiotic arrest and 154–5
 meiotic maturation and 166–8, 173–6, 177, 292
 oocyte maturity and 279
 cyclic AMP 26, 150, 153–6, 284
 follicle cell–oocyte transfer 154–5
 oocyte quality and 283
 purine-mediated meiotic arrest and 160–2, 163
 resumption of meiotic maturation 164–8, 173
 cyclic GMP 163
 cyclin 179
 cyclofenil 348
 cycloheximide 176
 cytochalasin 79, 83–5
 cytochrome P450_{arom} 211, 216, 220
 cytochrome P450_{sec} 211
 cytokines 225–33
 cytoplasmic bridges, oogonia 124, 126
 cytoplasmic microtubules 57, 71, 73–4
 cytoplasmic organelles 29–36
 cytoskeleton 54–89
 comparisons among mammals 88
 events mediated 55–6
 investigations on organization 54
 microfilament organization 76–88
 microtubule organization 57–73
 patterns of centrosome inheritance 73–6, 89
 cytostatic factor 26

 D14 protein 44
 decapeptyl (DTRP6) 287, 305
 del Castillo phenotype 112
 denuded oocytes (DO) 152, 181
 meiotic arrest 154, 155, 157, 161
 meiotic maturation 165, 173–4
 deuterotoky 4, 11
 development, oocyte 23–50, 119–46
 cytological aspects 27–38
 molecular aspects 38–46
 diacylglycerol 171, 172–3
 dibutyl cAMP (dbcAMP) 153, 155–6, 165–6,
 173–4
 synergistic interactions 157, 161
 5,6-dichloro-1- β -D-ribofuranosylbenimidazole 177
 dictyotene 28
Dicyaema 7
Didelphys 14
 20 α -dihydroxyprogesterone 293
 dimethyl sulphoxide (DMSO) 377, 378
 human oocyte cryopreservation 378, 383, 390,
 392
 rabbit oocyte cryopreservation 387–9
 6-dimethylaminopurine 179
 diploidy, human oocytes 96, 97, 99
 diplotene 27, 28, 129–31
 dipyridamole 160–1
 DNA methylation 133
 dominant follicles 194, 195
 dominant genes, premature ovarian failure 113–14
 donation
 embryo 335, 419
 oocyte 335, 417–18; age effects 281–2, 315; oocyte
 storage for 379
 donor insemination (DI) 335, 339–40, 346, 418
 Down's syndrome 141, 316
Drosophila 49, 111
 duties 397

 early pregnancy factor (EPF) 272
 ectopic germ cells 123–4

- ectopic pregnancy
 assisted conception and 346–7, 351
 clomiphene and 308–9
 hormonal influences 269
- EGF, *see* epidermal growth factor
- eggs 12–16
- embryos
 cryopreservation 376
 donation 335, 419
 mortality 402
 oviductal transport 271–2
 primordial germ cells 120–4
 research on human 409–11
 uterine retention 272
see also fertilized eggs
- endocytosis 34, 35, 44–5
- endogamy 4
- endometriosis 294–5, 402–3
 oocyte dysfunction 296–7, 309–10
 ovarian surgery 317
- endoplasmic reticulum (ER) 33–4, 36, 37
- β -endorphin 200, 283
- endosalpinx 254
- energy substrates 48, 173–6
- eosinophils 226–7
- epidermal growth factor (EGF) 214, 219–20
 meiotic maturation and 169, 220, 288
 receptors 219, 223
 TGF β interactions 219, 222
- Epostane 212
- 17 β -estradiol; estrogens, *see* 17 β -oestradiol;
 oestrogens
- ethical issues 352, 396–424
- Eutheria 13, 15–16
- evolution 1–20
 family 412–17
 gametes 6–8
 human monogamy 398–9
 outline 1–3
- extracellular matrix 222
- family
 closed domesticated nuclear 413–14
 cultural evolution 412–17
 open lineage 413
 restricted patriarchal nuclear 413
- family planning, oocyte cryopreservation 379
- Fasciola hepatica* 5
- fatty acids 158–9
- feminism 408–9
- fertility
 age effects 204, 281–2, 313–14
 contraceptive vaccines and 366–9
 culture and 401–5
 disability of high 404–5
 smoking and 321
see also infertility
- fertilization 9, 56
 delayed 284–5
in vitro, *see in vitro* fertilization
 microfilament organization 77–88
 microtubule organization 57–73
 oocyte maturity and 278, 293
 oocyte quality and 293
 specificity 16–18, 20, 360
 stages of egg maturation at 13, 15
see also sperm penetration
- fertilization rates 294–5
 classes of infertility 295–7
 endometriosis 296, 309, 310
 frozen/thawed human oocytes 378, 392
 maternal age and 315
 polycystic ovary disease 301
 smoking and 321–2
 unexplained infertility 296, 311–12, 313
- fertilized eggs 56
 microfilament organization 80, 81–5
 microtubule organization 57–9, 69, 72–3
 oviductal transport 270–2
 research on 409–11
see also embryos
- fertilizing capacity
 oocytes 278–9
 sperm 297–8, 363–6
see also quality, oocyte
- fetus
 follicle formation 134–6
 oocyte development 124, 125–9
- fibrinogen 283
- fibroblast growth factor (FGF) 222–3
 basic (bFGF) 214, 222–3
- fibronectin 222, 283
- fibrous lattices 35–6
- fimbria 254, 255
 oocyte uptake 256–7
- first cleavage (mitosis) 56
 microfilament organization 80, 85
 microtubule organization 57–9, 60, 72
- fission, whole-body 4, 5, 19
- fluorescein diacetate (FDA) 387, 388
- fluorescent recovery after photobleaching (FRAP)
 59–61
- fodrin 80, 85
- follicle-stimulating hormone (FSH) 131
 ageing and 204–5, 281, 317–18
 control of secretion 199, 201
 EGF interactions 219, 220
 FGF interactions 223
 follicle recruitment and 194–5
 IGF interactions 215

- IGFBP interactions 217, 218
 meiotic arrest and 153, 157, 158, 161
 meiotic maturation and 169, 170, 174–5
 myocardial cell responses 47
 oocyte quality and 282
 pituitary desensitization 341
 recombinant 343
 TGF β interactions 222
 therapy 339; chromosomal abnormalities and
 100; fertilization/implantation rates and 295;
 normal ovulatory women 305; oocyte quality
 and 307; polycystic ovary syndrome 287, 304,
 305; sperm premature chromosome
 condensation and 102
 TNF α antagonism 231–2
- follicles 133–41
 dominant 194, 195
 flushing 350
 formation (folliculogenesis) 133–6
 gate theory of selection 194
 Graafian 138, 151
 growth 136–41
 inhibition of oocyte maturation 25–7, 156–9,
 283–4
 oocyte interactions 46–9, 135–6
 oocyte release 256–7
 postnatal dynamics 141–3, 144
 primordial, *see* primordial follicles
 recruitment 136–41, 193–5
 removal of oocytes from 151–2
 steroidal autocrine/paracrine regulation
 210–12
 zona antigen immunization and 367–9
see also granulosa cells; theca cells
- follicular fluid (FF)
 composition; endometriosis 310; oocyte quality
 and 282–3, 293–4
 cytokines 230
 EGF 219
 IGFBPs 217–18
 inhibins 224
 inhibition of oocyte maturation 156–9, 160
 lymphocytes 227–9
 purines 159
 TGF β 221
- follicular phase
 early 193–4
 inhibitin secretion 199
 mid- 194–5
- foot processes, granulosa cells 28, 30, 38, 47
 forskolin 153, 154, 155, 157, 161, 165
 fossil record 1–3
 freezing, *see* cryopreservation
 FSH, *see* follicle-stimulating hormone
 fucoidan 361
- G proteins 154, 163, 197
 β -1,4-galactosyltransferase (gal-transferase) 46, 360,
 361
 gamete intrafallopian transfer (GIFT) 343, 346, 351
 gamete manipulation techniques 334, 335
 gametogenesis, animals 8–10
 gametophyte 12
 gamma-aminobutyric acid 265
 gap junctions 47
 biosynthesis 44
 meiotic arrest and 154–5, 164
 resumption of meiotic maturation and 166–8
 gate theory of follicle selection 194
gcd (*germ-cell deficient*) mutation 122
 genetic polymorphism 6
 genetics
 oocytes 95–105
 ovarian development 108–17
 genito-palato-cardiac syndrome 108
 genome
 imprinting 11
 reprogramming 133
 germ-cell determinant 8–9
 germ cell failure in both sexes 112, 116
 germ cells
 early history 120–4
 establishment of population 124–33
 growth and death 124–5
 numbers 125–9
 primordial, *see* primordial germ cells
 sexual differentiation 132–3
 germ-plasm theory 9, 119, 120
 germinal epithelium 129
 germinal vesicle 27–8, 29, 150
 breakdown (GVB) 55, 56, 151; *see also*
 maturation, meiotic
- glucose 48, 174–5
 glucose-6-phosphate dehydrogenase (G6PD) 44,
 133
 glucose phosphate isomerase (GPI) 44
 glycerol 377, 378
 glyceric acid 170
 glycolysis 175
 glycosaminoglycans 283
 GnRH, *see* gonadotrophin releasing hormone
 Golgi apparatus 28, 30–1
 gonadal dysgenesis
 XX 111–12, 113, 116
 XY 108
 gonadal ridge 120, 121
 gonadotrophin releasing hormone (GnRH; LHRH)
 299
 clinical deficiency 202–4, 299
 LH surge regulation 196–7
 pituitary receptors 197

- gonadotrophin releasing hormone agonists (GnRH-a)
 chromosomal abnormalities and 100
 IVF-related procedures 341–2, 343
 LH hypersecretion and 287, 288, 304–5
 oocyte quality and 307–8
 polycystic ovary syndrome 287, 304–5
 pulsed therapy 202–3, 302
 side effects 349
 sperm premature chromosome condensation and 102
see also pituitary desensitization
- gonadotrophin releasing hormone antagonists 343, 349
- gonadotrophin therapy 330, 335–6
 chromosomal abnormalities and 100
 LH hypersecretion 304–5
 maternal age and 314–15
 normal ovulatory women 305–7
 oocyte quality and 307
 polycystic ovary disease 301–2, 304–5
 side effects 349
 unexplained infertility 338
- gonadotrophins 129–31
 deficiency 298–9
 meiotic maturation and 150, 163, 164–8
see also follicle-stimulating hormone;
 human chorionic gonadotrophin; human
 menopausal gonadotrophins; luteinizing
 hormone
- Graafian follicles 138, 151
- granulocytes 226–7
- granulosa cells 28, 133–4, 136, 146
 autoimmune ovarian failure 319
 cancer chemotherapy and 319
 EGF actions 220
 FGF actions 223
 foot processes 28, 30, 38, 47
 IGF-binding proteins 216–17, 218
 IL-1 actions 230
 inhibin synthesis 224
 insulin-like growth factors (IGFs) 213–15
 meiotic maturation and 157–8
 oocyte interactions 46–9, 136
 polycystic ovary disease 301
 regulation of oestrodiol synthesis 210–11
 TGF β and 221, 222
 TNF α actions 232
 zona pellucida synthesis 362–3
- growth
 follicles 136–41
 oocytes 25–7, 150
- growth factors
 ovarian responses 214
 stimulation of meiotic maturation 168, 221
see also epidermal growth factor; fibroblast
 growth factor; transforming growth factor- β
- growth hormone (GH) 213–15
 recombinant 342
- growth releasing factor (GRF) 100
- GTP γ S 154, 163
- guanosine 161
- guanyl compounds 162, 163
- gynogenesis 4, 11
- hamster oocytes 14
 cryopreservation 377
 cytoskeletal organization 83, 86
 oviductal transport 262, 271
- HCG, *see* human chorionic gonadotrophin
- hemi-zona assay (HZA) 298, 363–4
- heterogamy 11–12
- heterosis 18
- heterotopic pregnancy 346–7, 351
- hexokinase 175
- hirsutism 300–1
- histamine 226, 235
- histone H1 kinase 179
- hMG, *see* human menopausal gonadotrophins
- hologamy 11
- Hominidae 2, 3
- Homo erectus* 2, 3, 19
- horse, oocyte transport 271, 272
- hox* genes 49
- human chorionic gonadotrophin (HCG) 337
 insemination treatments 340
 IVF-related procedures 341, 342, 343–4
 meiotic maturation and 165, 167, 168, 292–3
 side effects 349
 TGF β interactions 222
 unexplained infertility 338, 339
- human leucocyte antigen (HLA) homozygosity 312
- human menopausal gonadotrophins (hMG) 330
 chromosomal abnormalities and 100
 insemination treatments 340
 IVF-related procedures 340–1, 342
 normal ovulatory women 305
 polycystic ovary syndrome 287, 305
 side effects 349
 sperm premature chromosome condensation and 102
 unexplained infertility 338, 339
- human oocytes 14, 16, 23–4
 centrosome inheritance 76
 chromosomal abnormalities 95–105
 cryopreservation 376, 379–80, 393; applications
 378–9; pregnancy outcomes 392; studies 378,
 389–92
 cytology 32–3
 cytoskeletal organization 54, 71–3, 86, 88

- development 124, 125–9
 oviductal transport 269–70
 protein synthesis 44
 quality, *see* quality, oocyte
 size 25
- human pituitary glands (hPG) 330, 348
 humans, evolution 2, 3, 19
 hybrid vigour 18
 hybridization 18–19, 20
 11 β -hydroxysteroid dehydrogenase 293–4
 hyperprolactinaemia 299, 336
 hypothalamic–pituitary axis 196–7
 hypothalamic–pituitary dysfunction 202–4, 298–9
 hypoxanthine 159–63
 hypoxanthine guanine phosphoribosyl transferase (HPRT) 44, 162, 163
- IGFs, *see* insulin-like growth factor I; insulin-like growth factor II
- immaturity, oocyte, *see* maturity, oocyte
- immotile cilia syndrome 266
- implantation rates 294–5
 classes of infertility 295–7
 endometriosis 296, 309
 maternal age and 315–16
- in vitro* fertilization (IVF) 277, 407–9
 assessment of oocyte quality 278–80
 embryo research and 409–11
 ethical and legal status 352
 frozen/thawed oocytes 377, 378, 389
 history 331–2
 indices of success 294–5
 maternal age and 204, 281, 315, 317–18
 natural cycle 297
 oocyte storage 376, 378–9
 ovarian stimulation 340–4; luteal phase support 343–4; timing of hCG trigger injection 343
 pituitary desensitization 306, 341–2
 pregnancy outcomes 351–2
 related techniques 335
 smoking and 321–2
 sperm function assays 364, 365, 366
 surrogacy 335
 timing of insemination 279
- inbreeding 19, 20
- incorporation cone 82, 83, 88
- individualism, effective 412
- indomethacin 235
- infertility 405–11
 aetiology 329–30
 chromosomal abnormalities and 98–9, 104–5
 fertilization/implantation rates and 295–7
 male 296, 363–6
 paradox 402–4
- polycystic ovary syndrome 286
 range of treatments 333–5
 relative 406
 sperm premature chromosome condensation and 103
 treatment 330–1, 407–9
 tubal 294–5, 296, 312
 unexplained 295, 296–7, 406–7; LH hypersecretion 285–6; oocyte quality 311–13; ovarian stimulation 311, 337–9
see also assisted conception; fertility
- infundibulum (of oviduct) 254, 255
- inhibin 199–200, 201, 223–4
 control of synthesis 211
 effects of ageing 204–5
- inosine monophosphate (IMP) 162
- inosine monophosphate (IMP) dehydrogenase 162
- inositol trisphosphate (IP₃) 171–2, 197
- insemination
 artificial, by husband (AIH) 340
 delayed 284
 donor (DI) 335, 339–40, 346, 418
 intrauterine (IUI) 340
 methods 335
- insulin 213, 216, 217
- insulin-like growth factor I (IGF-I) 212–16, 217, 220, 221
 receptors 212
- insulin-like growth factor II (IGF-II) 212–13, 214, 216
 receptors 212
- insulin-like growth factor-binding protein-1 (IGFBP-1; PP12) 216–17, 220
- insulin-like growth factor-binding protein-2 (IGFBP-2) 217–18
- insulin-like growth factor-binding protein-3 (IGFBP-3) 217–18
- insulin-like growth factor-binding proteins (IGFBPs) 216–18
- integrin 38
- interferon-gamma (IFN- γ) 228, 229, 232–3
- interferons (IFNs) 232–3
- intergeneric crosses 18
- interleukin-1 (IL-1) 228, 229–31
- interleukin-1 receptors 229–30
- interleukin-6 (IL-6) 228, 231
- intracytoplasmic sperm injection (ICSI) 280, 296, 366
- intramural segment (of oviduct) 254, 256
- intrauterine insemination (IUI) 340
- iodoacetate 174
- irradiation 318–19
- 3-isobutyl-1-methylxanthine (IBMX) 153, 160–1, 165, 180
- isogamy 10, 11, 12

- isthmus (of oviduct) 254, 256
 oocyte transport 261
- K*-selection 400
- kallikreins 212
- Kallmann's syndrome (olfactogenital dysplasia)
 194, 202, 299
- kinetochores 65–7, 68
- c-kit* proto-oncogene 122, 123, 141
- lactate 48, 175
- lactate dehydrogenase (LDH) 44, 48
 heart-type (β -LDH) 42
- lactational amenorrhoea 400–401
- lamellae, annulate 33
- lampbrush chromosomes 28–9, 129
- laparoscopic oocyte recovery 349–50
- latrunculin 79, 81–2, 85
- lattices, fibrous 35–6
- leukocytes 225–33
- leukotrienes 233–4
- leuprolide acetate (Lucrin) 102, 341–2
- LH, *see* luteinizing hormone
- linoleic acid 158–9
- lipoxygenase products 233–4
- lithium 172
- luteal phase
 inhibin secretion 199, 224
 support, IVF-related procedures 341, 343–4
- luteinization 196
 EGF and 220
 premature 306–7
- luteinizing hormone (LH) 131
 effects of ageing 204, 317
 endometriosis 310
 hypersecretion 302–5; mechanism of action 303–4; oocyte quality and 285–8; polycystic ovary disease 286–7, 300–1, 302, 303; treatment 304–5
 normal cycle 337
 oocyte quality and 282
 pituitary desensitization and 341
 prostaglandin actions 234
 suppression, *see* pituitary desensitization
 surge 337; inhibin and 199–200, 201; oocyte maturation and 284–5, 292–3, 303–4; progesterone and 197–9; regulation 196–200
 therapy 307
- luteinizing hormone releasing hormone (LHRH), *see* gonadotrophin releasing hormone
- lymphocytes 227–9
- M-phase (maturation) promoting factor (MPF) 26, 102, 179–80
- Macaca mulatta* (rhesus monkeys) 72–3, 86, 88
- macrogametes 12–16
- macromolecules, biosynthesis and uptake 38–46
- macrophages 225–6
- male factor infertility 296, 363–6
- male partner
 age 314
 smoking 322
- mammalian oocytes 13–16, 23
 size 13–14, 15, 25
see also bovine oocytes; hamster oocytes; human oocytes; mouse oocytes; primate oocytes; rabbit oocytes; rat oocytes
- mammals
 centrosome inheritance 73–6
 evolution 2–3
 gametogenesis 9–10
 parthenogenesis 11
- marriage 396–7, 412–13
 companionate 414
- mast cells 226
- mate choice 397–8
- maturation, meiotic 25–7, 150–81
 cytological changes 27–38
 cytoskeletal organization 55, 56, 57–73, 77–88
 delayed fertilization after 284–5
 EGF and 169, 220
 energy substrates 173–6
 factors disturbing 292–4, 303–4
 inhibition by cAMP 153–6, 284
 inhibition by follicular components 25–7, 156–9, 283–4
 inhibition by purines 159–63
 resumption 163–73, 196; loss of inhibitory input 164–8; positive stimulation 168–73, 179–80; spontaneous versus ligand-induced 151–3
 RNA and protein synthesis 176–8
 TGF β and 221
- maturation promoting factor (MPF) 26, 102, 179–80
- maturity, oocyte
 assessment 278–9
 chromosomal abnormalities and 101
 cryopreservation and 379–80, 382–3
 at fertilization in different animals 13, 15
 fertilizing capacity and 278, 293
 micromanipulation and 280
- megalecithal eggs 12–13
- meiosis I 9–10
 abnormalities 127
 completion 151
 cytoskeletal organization 55, 56, 77–8
 metaphase 278–9
 prophase, *see* prophase of meiosis I
- meiosis II 10, 55, 56, 151
 metaphase, *see* metaphase II oocytes

- microfilament organization 78–9
 microtubule organization 57, 59–62, 69, 70, 71–2
 meiosis-inducing substance (MIS) 132
 meiosis-preventing substance (MPS) 132
 meiotic maturation, *see* maturation, meiotic
 meiotic spindles
 bovine oocytes 69, 70
 cryodamage 383
 human oocytes 71–2
 mouse oocytes 55, 56, 57, 59–62, 77–9
 membrana granulosa
 cumulus oophorus separation 166–8
 meiotic maturation and 175–6
 menarche, age at 399–400, 401
 menopause
 incipient 204–5, 317–18
 ovarian follicles 142–3, 144
 premature (POF) 113–14, 194
 menstrual cycle
 oviduct epithelial changes 266
 see also ovarian cycle
 mesonephric cells 128, 134–5
 mesosalpinx 254
 metaphase I oocytes 278–9
 metaphase II oocytes 55, 151
 assessment 278–9
 insemination 279
 microtubule organization 69, 70, 71
 metastatic tumour cells 121–2
 Metatheria 13, 15–16
 1-methyladenine 168
 methylamine 170
 microfilament inhibitors 79, 81–2, 83
 microfilaments 76–88
 other mammalian species 85–8
 rodent oocytes 77–85
 microgametes 11–12
 microlecithal eggs 12–13
 microtubule inhibitors 74, 79
 microtubule organizing centres (MTOCs), *see*
 centrosomes
 microtubules 57–73, 86, 88
 bovine oocytes 67–9
 cryodamage 384
 cytoplasmic 57, 71, 73–4
 mouse oocytes 57–67
 post-translational modification 62–5
 primate oocytes 71–3
 microvilli 28, 31, 38
 mid-follicular phase 194–5
 mifepristone 197, 198–9
 migration, primordial germ cells 9, 120–3
 miscarriage, *see* spontaneous abortion
 mitochondria 28, 30, 32–3, 36
 mitogen activated protein kinase 170
 mitosis
 first, *see* first cleavage
 oogonia 124–5
 mitotic spindles
 bovine eggs 69, 70
 mouse eggs 59
 MOM-1 41, 42
 monkey oocytes, *see* primate oocytes
 monocytes 225–6
 monogamy 398–9
 Monotremata (Prototheria) 13, 14–15
 moral standards 413, 415, 416
 morphology, oocyte 280
c-mos proto-oncogene 26, 178
 mouse
 follicle recruitment and growth 136–7, 138
 primordial germ cells 120–4
 zona antigen immunization 367
 mouse oocytes 24–5, 55, 56
 centrosome origins 57, 58, 59, 73–4, 75
 chromosomal abnormalities 101, 104
 cryopreservation 377, 383, 393
 cytological changes 27–38
 cytoskeletal organization 57–67, 77–85, 86
 development 124–5
 growth 25–7
 meiotic maturation 150–1, 153, 154, 155–6, 177,
 179
 oviductal transport 258, 262, 268
 synthesis and uptake of macromolecules 38–46
 mRNAs 40, 41–3
 multiple pregnancy 345–6
 mutations 6, 19
 myosalpinx 254
 oocyte transport 263–6, 270
 naked mole rats 18–19
 naltrexone 202, 203–4
 natural killer cells 229
 neomycin 172–3
 neuropeptides 265
 neutrophils 227
 nicotine 320, 321
 nocodazole 74
 non-disjunctions 95, 96, 97
 factors affecting frequency 101
 noradrenaline (norepinephrine) 47, 265
 ‘nuage’ 33
 nucleoli 29
 nucleotides 48
 numbers
 follicles 141–3
 germ cells 125–9
 oocytes 10, 141

- Oct-3* gene 133
- 17 β -oestradiol (E₂)
 ageing and 281
 chromosomal abnormalities and 101
 cyclic secretion 195, 196–7, 201, 337
 endometriosis 310
 meiotic arrest and 158
 oocyte quality and 282, 283, 293
 oocyte transport and 264–5, 269–70
 regulation of synthesis 210–11, 215
 smoking and 321
 stimulated cycles 338, 339, 341–2, 343
 unexplained infertility 311
- oestrogen receptors 211, 264
- oestrogens
 gonadotrophin therapy and 307
 oocyte quality and 303
 oocyte transport and 264–5, 266, 267, 268–70
 two-cell, two gonadotrophin model of synthesis 210–11
- okadaic acid 179–80
- olfactogenital dysplasia (Kallmann's syndrome) 194, 202, 299
- oligomenorrhoea 298, 299–300
 chemotherapy-induced 318–19
- oligospermia 404
- oocyte corona–cumulus complexes (OCCC) 279, 280
- oocyte–cumulus cell complex 47–8, 155, 166
- oogenesis 9–10, 23–50
 cytological aspects 27–38
 molecular aspects 38–46
- oogonia 9, 124–5, 126
 atresia 126–7
 cytoplasmic bridges 124, 126
- olemma 31, 38
 depolarization 359
 endocytosis 34, 35, 44–5
- ootid 9
- opioid peptides 200–2, 203–4
- organelles, cytoplasmic 29–36
- Ornithorhynchus anatinus* 15
- ovarian artery 256
- ovarian cancer 347–8
- ovarian cycle
 disordered, ovarian stimulation 337–9
 early follicular phase 193–4
 mid-follicular phase 194–5
 normal hormonal changes 337
 opioid peptides and 200–2
 regulation of LH surge 196–200
- ovarian development 120–46
 autosomal control 111–12
 genetic control 108–17
 molecular strategies 114–17
 postnatal 141–3
 prenatal 120–41
 X chromosome control 109–11
see also development, oocyte
- ovarian failure
 autoimmune 319–20
 complete 113
 incipient 204–5, 317–18
 premature (POF) 113–14, 194
- ovarian follicles, *see* follicles
- ovarian hyperstimulation syndrome 344–5, 378
- ovarian stimulation 334, 335–49
 chromosomal abnormalities and 99–100
 effects of ageing 317–18
 hazards 344–9
 insemination treatments 339–40
 IVF-related procedures 340–4
 LH hypersecretion 304–5
 oocyte quality and 282, 295, 307–9
 sperm premature chromosome condensation and 102
 unexplained infertility 311, 337–9
see also clomiphene; gonadotrophin therapy
- ovarian wedge resection 304
- ovariectomy, unilateral 317
- ovaries
 age-related changes in function 317–18
 cauterization 304
 enlarged, ovarian stimulation inducing 347
 paracrine regulation 210–36
 zona antigen immunization and 367–9
- oviduct
 anatomy 254–6
 blood supply 256
 epithelium 254–5
 innervation 256
 oocyte transport 257–72; at ampullary–isthmic junction 263; duration and time course 261–2; mechanical effector cells 263–7; methods of study 257–60; regulation 267–72
- ovigerous cords 134
- ovulation 9, 196
 bradykinin and 235
 clinical disorders 298–309
 cytokines and 230, 232
 effect of ageing 204–5
 endocrinology 193–205
 histamine and 226, 235
 induction, *see* ovarian stimulation
 monocytes/macrophages and 226
 oocyte uptake by fimbria 256–7
 progesterone and 197–9, 200, 201, 211–12
 prostaglandins and 196, 233–4, 235
 relaxin and 236

- ovum 12–16
 blighted 351
 oxygen radicals 234–5
 oxytocin 234
- p34^{cdc2} 179, 180
 p39^{mos} 178
 paedogenesis 4, 11
 papaverine 160–1
 paracentesis, abdominal 345
 paracrine regulation, ovarian function 210–36
Paramecium aurelia 7
Parascaris equorum 8–9
 parthenogenesis 4, 10–11, 19–20
 parthenogenetic activation 76
 bovine oocytes 69
 mouse oocytes 74, 75
 partial zona dissection/drilling (PZD) 280, 366
 periovarian bursa 257
 Perrault syndrome 112
 phorbol esters 168, 169, 172, 173
 phosphodiesterase (PDE)
 cAMP 154, 161, 163, 166
 inhibitors 153, 154, 160–1
 phosphoenolpyruvate 173
 phosphofructokinase 175
 phosphoinositide metabolites 170–3
 phospholipase A₂ 235
 phospholipase C 170–1, 172–3
 phyto-oestrogens 320
 pig oocytes
 meiotic maturation 157, 158, 176–7
 microfilament organization 85–7
 uterine transport 272
 zona pellucida 45
 pigs, zona antigen immunization 367
 pituitary desensitization 295, 309
 IVF-related procedures 306, 341–2
 ‘long’ protocols 305–6, 307–8
 normal ovulatory women 305–7
 polycystic ovary disease 304, 305
 ‘short’ protocols 305, 307–8, 342
 placental protein 12 (PP12; IGFBP-1) 216–17, 220
 plasminogen activator 47
 ovulation and 196, 212
 tissue-type (tPA), mRNA synthesis 41–2
Plasmodium vivax 5
 platelet activating factor (PAF) 272
 platelet-derived growth factor (PDGF) 214, 223
 polar body
 first 10, 55, 56; morphological assessment 280;
 oocyte maturity and 279
 second 56, 78–9, 81
 poly(A)+RNA 38–40
 polycyclic aromatic hydrocarbons 320–1
 polycystic ovary disease (PCOD) 299–302, 337–8,
 403
 IGF-binding proteins 218
 inhibin and 224
 insulin-like growth factors 215–16
 LH hypersecretion 286–7, 300–1, 302, 303
 oocyte quality 301–2
 ovarian hyperstimulation syndrome 344
 spontaneous abortions 301–2, 303
 treatment 304–5
 polyembryony 5
 polyploidy
 factors affecting frequency 100, 101, 104
 oocyte cryopreservation and 384–5, 390, 392,
 393
 polyspermy
 humans 76
 mechanism of prevention 359
 mouse oocytes 74
 ovarian stimulation and 100
 postmature oocytes 279
see also ageing, physiological oocyte
 pregnancy
 ectopic, *see* ectopic pregnancy
 heterotopic 346–7, 351
 multiple 345–6
 outcomes: assisted conception 351–2; oocyte
 cryopreservation 392
 α_1 -pregnancy-associated endometrial globulin
 (α_1 -PEG; IGFBP-1; PP12) 216–17, 220
 pregnancy rates
 insemination treatments 340
 IVF 332, 345, 346
 pituitary desensitization and 306
 polycystic ovary disease 301
 unexplained infertility 313
 pregnant mares’ serum gonadotrophins (PMSG)
 100
 premature chromosome condensation (PCC), sperm
 102–3
 premature ovarian failure (POF) 113–14, 194
 preterm delivery 345–6, 351
 primary oocytes 9, 150
 fertilization 15
 primate oocytes
 centrosome inheritance 76
 cryopreservation 378
 cytology 30, 36
 cytoskeletal organization 71–3, 86, 88
 primates, evolution 2–3
 primordial follicles 25, 135–6, 146
 atresia (attrition) 136–8, 316
 gate theory of selection 194
 recruitment 136–41, 193–5
 zona antigen immunization and 369

- primordial germ cells (PGCs) 8–9, 19, 120–4,
 145–6
 ectopic 123–4
 migration 9, 120–3
 origins 9, 119, 120, 145–6
 reprogramming of genome 133
 proacrosin 361
 production line hypothesis 138–40
 progesterone 196, 226
 control of ovulation 197–9, 200, 201, 211–12
 endometriosis 310
 luteal phase support 341, 343–4
 meiotic maturation and 158, 168
 normal cycle 337
 oocyte quality and 282, 283, 293
 oocyte transport and 264–5, 267, 268–70
 receptors 264
 TGF β and 221
 unexplained infertility 311
 programmed cell death (apoptosis)
 follicles 136–8
 at ovulation 196
 prolactin 283
 pronuclear apposition 83–5
 pronuclear envelope breakdown 56
 pronuclear formation 82
 1,2-propanediol 378, 383, 387, 391
 prophase of meiosis I 9, 129–33, 150
 fertilizing capacity 278
 prorenin 236
 prostaglandin E₁ (PGE₁) 265–6
 prostaglandin E₂ (PGE₂) 266, 271
 prostaglandin F_{2 α} (PGF_{2 α}) 234, 265–6
 prostaglandins 233–5
 oocyte transport and 265–6, 267, 271–2
 ovulation and 196, 233–4, 235
 protein kinase A (PKA) 153, 156, 169
 protein kinase C (PKC) 169, 171, 172, 197
 protein phosphorylation, meiotic maturation
 179–80
 protein synthesis inhibitors 176–7
 proteins
 biosynthesis 43–6
 meiotic maturation and 176–8
 storage 36, 37, 45, 50
 uptake 44–5
 Prototheria (Monotremata) 13, 14–15
 Protozoa/Protista 5, 6–7, 11, 19
 purines
 mechanisms of action on oocyte maturation
 160–3
 meiotic arrest and 159–60
 metabolic pathways 162
 puromycin 176, 177
 pyruvate 48, 173–4, 175, 176

 quality, oocyte 24, 277–88
 assessment 278–80, 297–8
 autoimmune ovarian failure 319–20
 clinical disorders affecting 292–322
 clinical indices 294–5
 endocrine influences 283–8
 endometriosis 309–10
 follicular microenvironment and 282–3, 293
 irradiation and cancer chemotherapy 318–19
 maternal age and 277–8, 280–2, 313–18
 ovarian stimulation and 282, 295, 307–9
 polycystic ovary syndrome 301–2
 smoking/environmental toxins and 320–2
 unexplained infertility 311–13

r-selection 400
 rabbit oocytes 14, 86
 centrosome inheritance 76
 cryopreservation 377–8, 383, 384, 387–9
 oviductal transport 259, 260, 262, 268, 270
 radiation therapy 318–19
 rat oocytes
 chromosomal abnormalities 104
 meiotic maturation 154, 155–6, 157, 177
 microfilament organization 79
 oviductal transport 258, 259, 262, 268, 270–2
 rats, pre-ovulatory LH surge 196–7
 recessive genes, premature ovarian failure 113
 recovery, oocyte 349–51
 laparoscopic 349–50
 ultrasound-directed 350–1
 relaxin 236
 religion 413, 415
 reproduction
 assisted, *see* assisted conception
 chromosomal abnormalities and 104–5
 diverse ways 3–6
 sexual 6–8, 11–16, 20
 reproductive choice 396–424
 research
 human embryos 409–11
 oocytes and spermatozoa 409–11
 rete ovarii 134, 146
 retrovirus-like particles 34
 rhesus monkeys (*Macaca mulatta*) 72–3, 86,
 88
 rhodanide 322
 ribonucleic acids, *see* RNA
 ribosomal protein genes 40–1
 ribosomal RNA 38–40
 ribosomes 35
rig gene 41
 rights 397
 animals 410

- RNA 29, 38–43
 transcription, meiotic maturation 176–8
 rodenticide 410
- sea urchin eggs 76, 86
 seasonal breeding 401
 secondary oocytes 9, 151
 fertilization 15
 secretory cells, oviduct epithelium 255, 267
 seeding, cryopreservation 381, 383
 Seitz's dictum 136
 self-fertilization 7
 Sertoli-cell only syndrome 112
 Sertoli cells 133–4, 146
 sex 398–9
 sex cords 134
 sex steroids, *see* androgens; oestrogens;
 progesterone
 sexual differentiation 132–3
 sexual maturation 399–400
 sexual reproduction 6–8, 11–16, 20
 sheep oocytes 14, 69
 centrosome inheritance 75–6
 cytoskeletal organization 85–7, 88
 meiotic maturation 176–7
 shell 14, 15
 shell membrane 14, 15
 size, oocyte 12, 13
 cryopreservation and 380, 383
 mammals 13–14, 15, 25
 smoking 320–2
 smooth muscle (cells), oviduct 254, 256, 263–6
 SP-56 protein 360–1
Spalacinae 18–19
 speciation 18–19
 species specificity, fertilization 16–18, 20, 360
 sperm
 acrosome defects 312
 assessment of function 297–8, 363–6
 cryopreservation 382
 donation 335, 339–40
 premature chromosome condensation (PCC)
 102–3
 sperm aster 57, 69, 70
 sperm dysfunction 296
 endometriosis and 310
 unexplained infertility 311, 312
 sperm penetration 16, 55–6
 blockage 312
 microfilaments and 81–3, 84, 88
see also fertilization
 sperm–oocyte fusion test 365–6
 sperm–zona interaction 16, 46, 357–62
 sperm–zona penetration tests 297, 365
 sperm–zona recognition assays 298, 363–5
 spironolactone 338
 spontaneous abortion (miscarriage) 294–5
 clomiphene and 308–9
 LH hypersecretion and 286, 287, 303
 pituitary desensitization and 304, 305
 polycystic ovary disease 301–2, 303
SRY (Sry) gene 132–3
staufen gene 49
 staurosporine 172
steel (Sl) gene 122, 123
 stem cell factor (SCF) 122, 123
 sterility 405–6
 chromosomal abnormalities and 98–9
 sperm premature chromosome condensation and
 103
see also infertility
 storage, oocyte 376–93
 storage materials 36, 37
 stress, oocyte transport and 270
 sub-zonal insemination (SUZI; SZI) 280, 366
 surrogacy 419–23
 altruistic 419–20, 421
 commercial 420–21, 422–3
 exploitation and autonomy 421–3
 gestational 420–21, 423
 IVF 335
 traditional (genetic-plus-gestational) 420, 422–3
 sympathetic nerves 256
 oocyte transport and 265, 270
 synaptonemal complexes 129
 syngamy 4, 8
- T lymphocytes 227–9
Tachyglossus aculeatus 14, 15
 tamoxifen 348
 teratomas 123
 testicular cords 133–4
 testosterone
 meiotic arrest and 158
 oocyte quality and 282
 polycystic ovary syndrome 300
 tetrahydrocannabinol 288
 TGF β , *see* transforming growth factor β
 theca cells 136
 autoimmune ovarian failure 319
 EGF and 219
 meiotic maturation and 158
 regulation of oestrodial synthesis 210–11
 TGF α synthesis 220
 theca-interstitial cells
 IL-1 actions 230
 insulin-like growth factors (IGFs) 213
 TGF β and 221–2
 TNF α actions 232
 thelytoky 4, 11

-
-
- toxins, environmental 143, 320–2
 transduction 8
 transformation 8
 transforming growth factor α (TGF α) 214, 219, 220, 221
 transforming growth factor β (TGF β) 214, 220–2, 223
 EGF interactions 219, 222
 germ cell migration and 122
 transport, oocyte 253–73
 oviducts 257–72
 uterus 272
 transvaginal oocyte recovery 350–1
 triploidy
 factors affecting frequency 100, 308
 humans 76
 trisomy 21 (Down's syndrome) 141, 316
 tubal infertility 294–5, 296, 312
 tubulin
 post-translational modification 62–5
 turnover in meiotic II spindle 59–60
 γ -tubulin 73
 tumour necrosis factor- α (TNF- α) 228, 231–2
 Turner's syndrome (45,X individuals) 108, 113, 127–8
 twinning, identical 5
 tyrosine kinase activity 361
- ultrasound-directed oocyte recovery 350–1
 uridine 47–8, 166
 uterine artery 256
 uterine lavage 419
 uterine tube, *see* oviduct
 utero-tubal junction (UTJ) 254, 256
 oocyte transport 261
 uterus
 age changes 315–16
 oocyte transport 272
- vaccines, contraceptive 366–9
 vasa gene 49
 vegetative reproduction 5
- vesicles 34–5
 virus-like particles 34
- W* (*White-spotting*) gene 122, 123
 weight loss 401
 wet-nursing 404–5
- X chromosome 108
 detection of genes 115
 inactivation/reactivation 133
 ovarian maintenance determinants 109–11
 premature ovarian failure and 113
 xanthine oxidase 162, 163
Xenopus oocytes 38–9
 XO karyotype 108, 113, 127–8
 XX gonadal dysgenesis 111–12, 113, 116
 with somatic anomalies 112
 XY gonadal dysgenesis 108
- Y chromosome 108, 132
 yolk 15
 mammalian 36, 50
 'yolk nucleus' 30
- zona-free hamster egg penetration 297, 365–6
 zona-free human egg penetration 366
 zona pellucida 14, 15–16, 31, 37, 357–70
 adhesion proteins 360–2
 biochemistry 359–60
 contraceptive vaccines and 366–9
 hardening (zona reaction) 359
 human salt-stored 298, 363
 protein synthesis 45–6, 362–3
 specificity of fertilization and 16, 360
 sperm function tests 298, 363–6
 sperm–zona interaction 16, 46, 357–62
- ZP1 45, 46, 359
 ZP2 45, 46, 359
 sperm interaction 46, 359, 361–2, 365
 ZP3 45, 46, 359–60
 immunization 367–9
 mRNA synthesis 41, 42–3, 362
 sperm interaction 46, 358–9, 360–1, 363